Percutaneous Rupture of Zygapophyseal Joint Cysts
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00837070|
Recruitment Status : Completed
First Posted : February 5, 2009
Last Update Posted : September 28, 2017
|Condition or disease||Intervention/treatment||Phase|
|Zygapophyseal Synovial Joint Cyst||Procedure: Percutaneous zygapophyseal cyst rupture||Phase 2|
Lumbar zygapophyseal joint cysts can cause lower extremity radiculopathy. These cysts can be cured by a minimally invasive technique: percutaneous cyst distention and rupture.
30 patient with lower extremity radiculopathy caused by lumbar zygapophyseal joint cysts will be included in the study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Percutaneous Rupture of Zygapophyseal Joint Cysts|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||January 2012|
Percutaneous zygapophyseal cyst rupture
Procedure: Percutaneous zygapophyseal cyst rupture
Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
Other Name: Axiom Artis Siemens
- VAS(Visual analogue scale)for extremity pain [ Time Frame: 1-3 and 12 months after intervention ]
- Roland-Morris disability index [ Time Frame: 1-3 and 12 months after intervention ]
- Reduction of cyst size based om T2 MRI [ Time Frame: 3 and 12 months after intervention ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00837070
|Departement of Neuroradiology Oslo university hospital avd Ullevaal|
|Oslo, Norway, 0407|
|Principal Investigator:||Øivind Gjertsen, Md, Msc||Oslo University Hospital|